Summary: In a crossover trial in adults with type 2 diabetes on metformin, a specific Bifidobacterium animalis probiotic blunted the rise in fasting glucose and insulin resistance and raised immunoglobulin levels over 6 weeks, with the authors describing the benefits as modest and adjunctive.
PICO Summary
| Element | Detail |
|---|---|
| Population | 44 Thai adults (35–65) with type 2 diabetes on metformin monotherapy; randomised, double-blind, placebo-controlled crossover trial. |
| Intervention | Bifidobacterium animalis subsp. lactis TISTR 2591 (1×10⁹ CFU/g/day) for 6 weeks. |
| Comparison | Placebo, with 4-week washout and crossover. |
| Outcome | The probiotic attenuated the rise in fasting glucose (Δ +1.14 vs +12.57 mg/dL; p<0.001), limited the increase in HOMA-IR (p=0.006), and improved HOMA-β (p<0.001). It raised IgM and IgG (p<0.001), reduced LDL-C (p=0.009) and cathepsin D (p=0.005), with no change in IL-6, adiponectin, MDA, hs-CRP, or body composition. No serious adverse effects. |
Bifidobacterium animalis & glycemic control in T2D
Crossover RCT · type 2 diabetes · 6 weeks
A strain-specific probiotic blunted the rise in fasting glucose and insulin resistance over 6 weeks, a modest adjunctive benefit on top of metformin rather than an active glucose-lowering effect.
Expert Commentary
This is a methodologically solid small trial whose crossover design lends credibility, since each participant served as their own control and baseline microbiome variation is otherwise a major confounder. The result deserves precise description, though, because the glycaemic effect was largely about preventing worsening rather than producing improvement: glucose rose in both arms but rose far less with the probiotic, alongside a smaller climb in insulin resistance and better beta-cell indices. The immune finding is real but specific, namely higher immunoglobulins, while the classic inflammatory markers IL-6 and hs-CRP did not change, so I would not overstate an anti-inflammatory effect. The authors’ own framing of modest, adjunctive benefit is the right register. Limitations include a short six weeks, only 44 participants, a single Thai population whose baseline microbiota may differ from others, and a specific strain unlikely to be available elsewhere, which matters because probiotic effects are strain-specific. Can I use this with my patients? Yes, as a low-risk adjunct with honest expectations. For a patient already on proven therapy who wants a gut-health add-on, this is reasonable, while I would be clear the glycaemic effect is small and would never let it substitute for established treatment.
References
Khiaolaongam W, Boonyapranai K, Sitdhipol J, et al. Bifidobacterium animalis subsp. lactis TISTR 2591 improves glycemic control and immune response in adults with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled crossover clinical trial. Nutrients. 2025;17(19):3097. doi:10.3390/nu17193097